2020
DOI: 10.2337/dc19-1294
|View full text |Cite
|
Sign up to set email alerts
|

Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
13
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(15 citation statements)
references
References 3 publications
2
13
0
Order By: Relevance
“…A finding in this study is that medication costs, particularly for insulin, may impact adherence. This is in line with the rising cost of insulin in the U.S. and out of pocket expenses for patients under Medicare Part D plans [ 39 ]. Additionally, a recent study evaluating approximately 165,000 adult patients (<65 years of age) with diabetes reported 41% had financial difficulties from medical bills, and approximately 50% showed cost-related medication non-adherence [ 40 ].…”
Section: Discussionsupporting
confidence: 54%
“…A finding in this study is that medication costs, particularly for insulin, may impact adherence. This is in line with the rising cost of insulin in the U.S. and out of pocket expenses for patients under Medicare Part D plans [ 39 ]. Additionally, a recent study evaluating approximately 165,000 adult patients (<65 years of age) with diabetes reported 41% had financial difficulties from medical bills, and approximately 50% showed cost-related medication non-adherence [ 40 ].…”
Section: Discussionsupporting
confidence: 54%
“…From 2013 to 2015, prescription drug prices increased annually by 10%, six times the rate of general inflation (29). An earlier study found that increased insulin prices led to an OOP cost burden for Medicare beneficiaries with diabetes, even after closure of the coverage gap in Part D benefits under the Affordable Care Act (31).…”
Section: Discussionmentioning
confidence: 99%
“…Participants in the standard Part D plan have OOP insulin costs surpassing $1,000. Despite closing the coverage gap and the expected reduction in OOP costs, insulin prices increased by 55% from 2014 to 2019 (29,30). Another important trend affecting overall costs for insulin is the shift in insulin use from the less expensive human insulins to more expensive human insulin analogs (31).…”
Section: Factors Associated With Crnmentioning
confidence: 99%